Veracyte VCYT 深 沪
等待开盘 10-16 09:30:00 美东时间
44.39
+0.880
+2.02%
华盛通- 最 高45.5799
- 今 开43.36
- 成交量 122.72万股
- 最 低 42.70
- 昨 收 43.51
- 总市值 35.69亿
- 52周最高 60.91
- 市盈率 静 53.90
- 换手率 1.53%
- 52周最低 29.455
- 委 比 -11.55%
- 总股本 8039.07万
- 历史最高 86.03
- 量 比 1.22
- 振 幅 6.62%
- 历史最低 4.21
- 每 手 1
- 风险率 7.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMD
Cathie Wood’s Ark Invest stepped up its semiconductor, biotechnology and technology exposure during the week ended October 2, with Nvidia (NVDA) and Intellia Therapeutics (NTLA) leading its buying act...
10-05 18:47
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, leveraging his 20+ years of biotech experience, including over $2B in oncology partnerships. Donigian will help advance Sutro’s ADC platform and pipeline, including STRO-004, STRO-006, and STRO-227, while building strategic collaborations. He previously led business development at Zymeworks and NanoString Technologies. Sutro granted Donigian stock options and...
09-29 12:00
Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026
Veracyte, Inc. announced that eight studies leveraging its Decipher Prostate Genomic Classifier test will be presented at the 2026 ASTRO Annual Meeting in Boston. These studies focus on Decipher’s ability to assess prostate cancer risk and predict patient responses to treatment intensification, such as adding androgen-deprivation therapy to radiation. The presentations include analyses from clinical trials, genomic research, and real-world studie...
09-25 21:12
美股牛股 | Grail升逾15%，Galleri癌症筛查工具获FDA专家组支持；Everpure升逾11%，2028财年业绩预测超分析师预期
Grail升逾15%，Galleri癌症筛查工具获FDA专家组支持；Everpure升逾11%，2028财年业绩预测超分析师预期>>
09-25 19:00
Muse一夜爆红！“木头姐”大手笔增持Meta，加码医疗与生物科技
当地时间9月22日，“木头姐”Cathie Wood旗下方舟投资（ARK Invest）公布的每日交易纪录显示，持股重心明显偏向大型AI平台与基因精准医疗，同时...
09-23 09:49
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood is doubling down on biotech, but investors looking beyond her ARK Genomic Revolution ETF (BATS:ARKG) have several other ways to gain exposure to the same companies. ARKG bought about $4.5 million of Ionis Pharmaceuticals Inc (NASDAQ:IONS), nearly $3 million of Veracyte Inc (NASDAQ:VCYT),...
09-22 22:40
Veracyte acquiring Convergent Genomics in up to $180M deal
Veracyte (VCYT) has agreed to buy Convergent Genomics, which is focused on urologic cancer diagnostics, for $150M upfront. The acquisition gives Veracyte, which provides cancer genomic tests, access t...
09-15 04:32
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform
Veracyte, a leading cancer diagnostics company, announced the acquisition of Convergent Genomics, gaining access to their UroAmp platform, which uses proprietary utDNA technology to improve bladder cancer care. UroAmp analyzes tumor-derived genomic information from urine, offering insights for therapy-response monitoring and post-treatment surveillance, particularly for non-muscle invasive bladder cancer (NMIBC). The acquisition strengthens Verac...
09-14 20:05
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
UBS Maintains Buy on Veracyte, Raises Price Target to $65
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $52 to $65.
09-10 02:01
